Condition (MeSH)
Mastocytosis, Cutaneous
ClinicalTrials.gov lists 13 trials for Mastocytosis, Cutaneous or a narrower condition beneath it. Blueprint Medicines Corporation has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
9 of the 13 trials are tagged with Mastocytosis, Cutaneous itself; the rest are tagged with a narrower condition beneath it.
When did Mastocytosis, Cutaneous trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2021 | 3 |
| 2020 | 1 |
| 2018 | 1 |
| 2016 | 1 |
| 2015 | 2 |
| 2007 | 1 |
| 2006 | 1 |
| 2002 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 13 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Mastocytosis, Cutaneous trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 3 |
| Not applicable | 3 |
| Observational | 7 |
How many Mastocytosis, Cutaneous trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Completed | 8 |
| Terminated | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Mastocytosis, Cutaneous trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Blueprint Medicines Corporation | 2 |
| Cogent Biosciences, Inc. | 1 |
| JADO Technologies GmbH | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
Which drugs are being tested for Mastocytosis, Cutaneous? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Bezuclastinib | 1 |
Interventions as named in the registry (1)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| TF 002 | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Mastocytosis, Cutaneous? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. | The journal of allergy and clinical immunology. In practice | 2021 | Yes |
| Frequency of isolated cutaneous involvement in adult mastocytosis: a cohort study. | Journal of the European Academy of Dermatology and Venereology : JEADV | 2019 | Yes |
| Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. | The Journal of allergy and clinical immunology | 2016 | Yes |
| Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. | Allergy | 2013 | Yes |
| Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. | American journal of hematology | 2010 | Yes |
Showing 5 of 7 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Cutaneous mastocytosis | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Cutaneous mastocytosis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Cutaneous mastocytosis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Cutaneous mastocytosis | 66646 | Exact | Orphadata Science knowledge files, Product 1 |
| Cutaneous mastocytosis | 66646 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials.